28 January 2019 : Laboratory Research
Sulforaphane Attenuates H₂O₂-induced Oxidant Stress in Human Trabecular Meshwork Cells (HTMCs) via the Phosphatidylinositol 3-Kinase (PI3K)/Serine/Threonine Kinase (Akt)-Mediated Factor-E2-Related Factor 2 (Nrf2) Signaling Activation
Yuzhen Liu1ABCD, Pan Liu1ABCD, Qiang Wang2AEG*, Fengmei Sun3BCF, Fang Liu4ABCDDOI: 10.12659/MSM.913849
Med Sci Monit 2019; 25:811-818
Abstract
BACKGROUND: The aim of this study was to investigate whether and how sulforaphane (SFN), a novel promising nuclear factor-E2-related factor 2 (Nrf2) activator, exerted antioxidative stress through activating Nrf2 signaling.
MATERIAL AND METHODS: Cultured human trabecular meshwork cells (HTMCs) were treated with SFN for 6 hours after establishing the oxidative stress model by hydrogen peroxide (H₂O₂). The cell viability, the level of intercellular reactive oxygen species (ROS), and the apoptosis rate were observed using various kits. In addition, the gene and protein expression of Nrf2 and the phase II antioxidative enzymes were determined by performing qRT-PCR and western blotting.
RESULTS: In H₂O₂-treated HTMCs, SFN protected HTMCs from oxidative stress damage and decreased the intracellular ROS accumulation, thus inhibiting cell apoptosis. SFN also increased the gene and protein expression of phase II antioxidative enzymes such as NAD(P)H: quinone oxidoreductase 1 (NQO-1), heme oxygenase-1 (HO-1), glutamate-cysteine ligase catalytic subunit (GCLC), and glutamate-cysteine ligase modifier subunit (GCLM) by Nrf2-dependent pathway. Furthermore, investigations of the pathway showed that HTMCs pretreated with LY294002, an inhibitor of phosphatidylinositol 3-kinase (PI3K), downregulated the expression of phase II antioxidative enzymes, partly.
CONCLUSIONS: These results indicated a novel application for SFN in attenuating H₂O₂-induced oxidative stress in HTMCs through activating PI3K/Akt/Nrf2 signaling pathway.
Keywords: Phosphatidylinositol 3-Kinases, Proto-Oncogene Proteins c-akt, Isothiocyanates, NF-E2-Related Factor 2, Oxidants, phosphatidylinositol 3-kinase, Phosphatidylinositols, Sulfoxides, Trabecular Meshwork
Editorial
01 May 2024 : Editorial
Editorial: First Regulatory Approval for Adoptive Cell Therapy with Autologous Tumor-Infiltrating Lymphocytes (TILs) – Lifileucel (Amtagvi)DOI: 10.12659/MSM.944927
Med Sci Monit 2024; 30:e944927
In Press
12 Mar 2024 : Clinical Research
Tissue Inhibitors of Metalloproteinase 1 (TIMP-1) and 3 (TIMP-3) as New Markers of Acute Kidney Injury Afte...Med Sci Monit In Press; DOI: 10.12659/MSM.943500
12 Mar 2024 : Review article
Optimizing Behçet Uveitis Management: A Review of Personalized Immunosuppressive StrategiesMed Sci Monit In Press; DOI: 10.12659/MSM.943240
12 Mar 2024 : Clinical Research
Metabolomic Alterations in Methotrexate Treatment of Moderate-to-Severe PsoriasisMed Sci Monit In Press; DOI: 10.12659/MSM.943360
14 Mar 2024 : Clinical Research
Renal Dysfunction Increases Risk of Adverse Cardiovascular Events in 5-Year Follow-Up Study of Intermediate...Med Sci Monit In Press; DOI: 10.12659/MSM.943956
Most Viewed Current Articles
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952